MSD's Delstrigo can be prescribed in general hospitals

After registering insurance benefits in October, it passed DC at medical institutions such as Severance

The DRIVE-AHEAD study demonstrated its effectiveness

Delstrigo, an HIV combination that succeeded in registering insurance benefits, is preparing to enter the market in earnest.

 

According to related industries, the HIV combination Delstrigo ( Doravirine 100 mg, Lamivudine 300 mg and Tenofir Disoproxil Fumarate), which is taken once a day by MSD Korea, has now passed the DC of medical institutions such as Sinchon Severance Hospital.

 

The drug was approved in Korea in January last year, submitted a benefit application at the beginning of this year, and was listed in January.

 

Delstrigo's benefit indication is "the treatment of HIV-1 infection in adults who have no previous anti-retrovirus treatment experience." Among the ingredients, Doravirine 100mg was approved by the MFDS under the brand name Pipeltro as of November 22, 2019, and is required to be administered in combination with other anti-retroviral drugs.

 

Both Pipeltro and Delstrigo received indications for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients who had no previous anti-retroviral treatment experience.

 

Delstrigo was confirmed its validity through DRIVE-AHEAD clinical trials.

 

In the clinical trial, Delstrigo proved non-equivalence compared to therapy of Efavirenz ·Emtricitabine·Tenofovir.

 

The proportion of patients who reached viral inhibition (less than 40 copies/mL of HIV-1 RNA) at 48 weeks was 84% in Delstrigo treatment group and 80% in EFV/FTC/TDF treatment group.

 

The rate of discontinuation of treatment due to adverse reactions was 3% and 6.6%, respectively, which was lower in the Delstrigo treatment group.

 

Meanwhile, Gilead, GSK, MSD, Janssen, AbbVie, and BMS are currently competing in the HIV sector, of which Gilead and GSK account for about 90% of the market.